Equities analysts predict that Portola Pharmaceuticals Inc (NASDAQ:PTLA) will post earnings per share (EPS) of ($1.52) for the current quarter, according to Zacks. Two analysts have issued estimates for Portola Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($1.67) and the highest estimate coming in at ($1.37). Portola Pharmaceuticals posted earnings per share of ($0.95) during the same quarter last year, which indicates a negative year over year growth rate of 60%. The firm is expected to announce its next quarterly earnings report on Tuesday, February 27th.
According to Zacks, analysts expect that Portola Pharmaceuticals will report full year earnings of ($4.94) per share for the current financial year, with EPS estimates ranging from ($5.15) to ($4.65). For the next financial year, analysts expect that the business will post earnings of ($3.45) per share, with EPS estimates ranging from ($4.74) to ($2.66). Zacks Investment Research’s EPS averages are a mean average based on a survey of analysts that that provide coverage for Portola Pharmaceuticals.
Portola Pharmaceuticals (NASDAQ:PTLA) last released its quarterly earnings data on Monday, November 6th. The biopharmaceutical company reported ($1.41) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.49) by $0.08. The company had revenue of $3.83 million during the quarter, compared to analysts’ expectations of $4.71 million. Portola Pharmaceuticals had a negative net margin of 938.19% and a negative return on equity of 110.46%. The firm’s revenue for the quarter was down 58.9% on a year-over-year basis. During the same quarter in the previous year, the company earned ($1.64) earnings per share.
In related news, Director Henry Ward Wolff sold 12,000 shares of the company’s stock in a transaction dated Friday, December 15th. The shares were sold at an average price of $47.00, for a total transaction of $564,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 5.50% of the stock is currently owned by corporate insiders.
Large investors have recently bought and sold shares of the business. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Portola Pharmaceuticals by 14.2% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,078 shares of the biopharmaceutical company’s stock valued at $117,000 after purchasing an additional 258 shares during the last quarter. Jacobi Capital Management LLC acquired a new position in shares of Portola Pharmaceuticals in the 2nd quarter worth approximately $125,000. IFP Advisors Inc lifted its holdings in shares of Portola Pharmaceuticals by 7.7% in the 2nd quarter. IFP Advisors Inc now owns 2,370 shares of the biopharmaceutical company’s stock worth $133,000 after acquiring an additional 170 shares during the last quarter. QS Investors LLC acquired a new position in shares of Portola Pharmaceuticals in the 2nd quarter worth approximately $147,000. Finally, Oppenheimer Asset Management Inc. lifted its holdings in shares of Portola Pharmaceuticals by 251.2% in the 3rd quarter. Oppenheimer Asset Management Inc. now owns 2,862 shares of the biopharmaceutical company’s stock worth $155,000 after acquiring an additional 2,047 shares during the last quarter. Institutional investors own 87.25% of the company’s stock.
Portola Pharmaceuticals (PTLA) traded up $0.58 during mid-day trading on Friday, hitting $47.60. 714,300 shares of the stock were exchanged, compared to its average volume of 966,766. The company has a debt-to-equity ratio of 0.24, a current ratio of 8.31 and a quick ratio of 8.31. Portola Pharmaceuticals has a twelve month low of $18.63 and a twelve month high of $67.10.
WARNING: “Portola Pharmaceuticals Inc (PTLA) Expected to Announce Earnings of -$1.52 Per Share” was originally published by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this article on another domain, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this article can be accessed at https://sportsperspectives.com/2017/12/19/portola-pharmaceuticals-inc-ptla-expected-to-announce-earnings-of-1-52-per-share.html.
Portola Pharmaceuticals Company Profile
Portola Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. The Company’s two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Portola Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.